Lawson Kroeker Investment Management Inc. NE Buys 1,718 Shares of Elevance Health, Inc. (NYSE:ELV)

Lawson Kroeker Investment Management Inc. NE raised its position in Elevance Health, Inc. (NYSE:ELV - Free Report) by 5.4% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 33,806 shares of the company's stock after buying an additional 1,718 shares during the period. Elevance Health comprises 2.7% of Lawson Kroeker Investment Management Inc. NE's investment portfolio, making the stock its 10th biggest position. Lawson Kroeker Investment Management Inc. NE's holdings in Elevance Health were worth $14,704,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Accredited Wealth Management LLC purchased a new stake in shares of Elevance Health during the fourth quarter worth about $25,000. Flagship Wealth Advisors LLC purchased a new stake in shares of Elevance Health during the fourth quarter worth about $26,000. OFI Invest Asset Management purchased a new stake in shares of Elevance Health during the fourth quarter worth about $29,000. WealthTrak Capital Management LLC purchased a new stake in shares of Elevance Health during the fourth quarter worth about $29,000. Finally, Lee Danner & Bass Inc. purchased a new stake in shares of Elevance Health during the fourth quarter worth about $30,000. Hedge funds and other institutional investors own 89.24% of the company's stock.

Elevance Health Trading Down 0.4%

NYSE:ELV traded down $1.33 on Thursday, hitting $348.92. The stock had a trading volume of 2,006,213 shares, compared to its average volume of 1,607,108. The company has a quick ratio of 1.43, a current ratio of 1.43 and a debt-to-equity ratio of 0.66. The stock has a market cap of $78.83 billion, a price-to-earnings ratio of 13.61, a PEG ratio of 0.89 and a beta of 0.60. The company has a fifty day moving average price of $389.10 and a two-hundred day moving average price of $398.31. Elevance Health, Inc. has a 1-year low of $347.37 and a 1-year high of $567.26.

Elevance Health (NYSE:ELV - Get Free Report) last posted its earnings results on Tuesday, April 22nd. The company reported $11.97 earnings per share for the quarter, beating the consensus estimate of $10.60 by $1.37. The company had revenue of $48.77 billion for the quarter, compared to analyst estimates of $46.26 billion. Elevance Health had a net margin of 3.23% and a return on equity of 18.61%. Equities research analysts expect that Elevance Health, Inc. will post 33.96 earnings per share for the current fiscal year.

Elevance Health Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, June 25th. Stockholders of record on Tuesday, June 10th were issued a $1.71 dividend. The ex-dividend date of this dividend was Tuesday, June 10th. This represents a $6.84 annualized dividend and a dividend yield of 1.96%. Elevance Health's dividend payout ratio is currently 26.69%.

Insider Activity at Elevance Health

In other news, CFO Mark Kaye sold 4,588 shares of the company's stock in a transaction that occurred on Thursday, April 24th. The shares were sold at an average price of $424.82, for a total value of $1,949,074.16. Following the transaction, the chief financial officer directly owned 18,977 shares in the company, valued at approximately $8,061,809.14. This represents a 19.47% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.29% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the stock. Royal Bank Of Canada reissued an "outperform" rating and set a $478.00 target price on shares of Elevance Health in a research note on Wednesday, June 4th. Truist Financial set a $500.00 price target on shares of Elevance Health and gave the stock a "buy" rating in a research report on Monday, June 9th. Sanford C. Bernstein restated an "outperform" rating on shares of Elevance Health in a research report on Friday, March 28th. Argus set a $465.00 price target on shares of Elevance Health in a research report on Friday, April 25th. Finally, Mizuho boosted their price target on shares of Elevance Health from $455.00 to $505.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 9th. Four equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. Based on data from MarketBeat, Elevance Health has a consensus rating of "Moderate Buy" and an average target price of $498.87.

Elevance Health Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.